Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis-Reference-Cited by-同舟云学术

Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

Published:2016-08-09 Issue:1 Volume:26 Page:28-35
ISSN:0906-6705
Container-title:Experimental Dermatology
language:en
Short-container-title:Exp Dermatol

Author:

Khattri Saakshi¹²,Brunner Patrick M.¹,Garcet Sandra¹,Finney Robert³,Cohen Steven R.⁴,Oliva Margeaux¹²,Dutt Riana¹²,Fuentes-Duculan Judilyn¹,Zheng Xiuzhong¹,Li Xuan¹,Bonifacio Kathleen M.¹,Kunjravia Norma¹,Coats Israel¹,Cueto Inna¹,Gilleaudeau Patricia¹,Sullivan-Whalen Mary¹,Suárez-Fariñas Mayte¹²⁵⁶,Krueger James G.¹,Guttman-Yassky Emma¹²

Affiliation:

1. The Laboratory for Investigative Dermatology; The Rockefeller University; New York NY USA

2. Department of Dermatology and the Laboratory for Inflammatory Skin Diseases; Icahn School of Medicine at Mount Sinai; New York NY USA

3. Department of Dermatology; Jefferson Medical College; Philadelphia PA USA

4. Division of Dermatology; Department of Medicine; Albert Einstein College of Medicine; New York NY USA

5. Department of Population Health Science and Policy; Icahn School of Medicine at Mount Sinai; New York NY USA

6. Icahn Institute for Genomics and Multiscale Biology at Mount Sinai; Icahn School of Medicine at Mount Sinai; New York NY USA

Funder

Janssen Pharmaceuticals

National Center for Advancing Translational Sciences

National Institutes of Health

Clinical and Translational Science Award (CTSA)

Publisher

Wiley

Subject

Dermatology,Molecular Biology,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/exd.13112/fullpdf

Reference44 articles.

1. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis;Guttman-Yassky;J Allergy Clin Immunol,2007

2. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells;Nograles;J Allergy Clin Immunol,2009

3. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications;Czarnowicki;J Allergy Clin Immunol Pract,2014

4. Contrasting pathogenesis of atopic dermatitis and psoriasis-part II: immune cell subsets and therapeutic concepts;Guttman-Yassky;J Allergy Clin Immunol,2011

5. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm;Eyerich;Allergy,2013

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting immunotherapeutic strategies for the management of atopic dermatitis;Exploration of Asthma & Allergy;2024-08-09

2. Systemic Immunomodulatory Treatments for Atopic Dermatitis;JAMA Dermatology;2024-07-17

3. Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: Mechanistic considerations;Journal of Allergy and Clinical Immunology;2024-07

4. Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease;Journal of the American Academy of Dermatology;2024-07

5. Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy;Current Pharmaceutical Biotechnology;2024-06-25